Spermosens AB (SPERM.ST)
SEK 0.01
(2.27%)
SEK 0.01
(2.27%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -10.89 Million SEK | 12.97% |
| 2022 | -12.51 Million SEK | -103.5% |
| 2021 | -6.15 Million SEK | -201.22% |
| 2020 | -2.04 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -2.68 Million SEK | -75.51% |
| 2024 Q2 | -2.09 Million SEK | 22.03% |
| 2024 Q3 | -2.15 Million SEK | -2.82% |
| 2023 FY | -10.89 Million SEK | 12.97% |
| 2023 Q4 | -1.53 Million SEK | 45.5% |
| 2023 Q2 | -3.4 Million SEK | -4.68% |
| 2023 Q1 | -3.24 Million SEK | -3.87% |
| 2023 Q3 | -2.8 Million SEK | 17.38% |
| 2022 Q4 | -3.12 Million SEK | 1.73% |
| 2022 Q3 | -3.18 Million SEK | 14.0% |
| 2022 Q2 | -3.7 Million SEK | -47.53% |
| 2022 Q1 | -2.5 Million SEK | -84.68% |
| 2022 FY | -12.51 Million SEK | -103.5% |
| 2021 Q1 | -885 Thousand SEK | 38.58% |
| 2021 Q4 | -1.35 Million SEK | 30.47% |
| 2021 FY | -6.15 Million SEK | -201.22% |
| 2021 Q3 | -1.95 Million SEK | 0.15% |
| 2021 Q2 | -1.95 Million SEK | -121.02% |
| 2020 Q3 | -485 Thousand SEK | -212.9% |
| 2020 FY | -2.04 Million SEK | 0.0% |
| 2020 Q2 | -155 Thousand SEK | 0.0% |
| 2020 Q4 | -1.44 Million SEK | -197.11% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AroCell AB (publ) | -59.78 Million SEK | 81.778% |
| Devyser Diagnostics AB (publ) | -56.5 Million SEK | 80.719% |
| Immunovia AB (publ) | -296.46 Million SEK | 96.325% |
| Prostatype Genomics AB (publ) | -39.3 Million SEK | 72.284% |
| SenzaGen AB | -14.74 Million SEK | 26.092% |